Ann: Immutep AGM 2021 - CEO's Presentation, page-3

Marc mentioned that it's possible that BMS might get regulatory approval for their Lag 3 product for melanoma in March of 2022.

If that happens, IMM could well see a nearology re-rating of the share price.



U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

U.S. Food and Drug Administration assigns a target action date of March 19, 2022

Bristol Myers Squibb - U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma (bms.com)

.